Lexaria Bioscience (LEXX) Cost of Revenue (2017 - 2024)

Lexaria Bioscience has disclosed Cost of Revenue across 8 years of filings, most recently posting $2720.0 for Q4 2024.

• Cost of Revenue for Q4 2024 came in at $2720.0, down 43.59% year-over-year; the trailing twelve-month figure through Aug 2025 was $2720.0 (down 43.59% YoY), and the FY2025 annual result was $2720.0, down 43.59% from the prior year.
• Cost of Revenue came in at $2720.0 for Q4 2024 at Lexaria Bioscience, down from $4822.0 in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $64478.0 in Q4 2020 to a low of $2720.0 in Q4 2024.
• The 5-year median for Cost of Revenue is $17215.0 (2022), against an average of $23609.6.
• Across the five-year window, Cost of Revenue jumped 2060.07% in 2020 and tumbled 91.36% in 2021, its largest moves.
• Lexaria Bioscience's Cost of Revenue stood at $64478.0 in 2020, then sank by 91.36% to $5570.0 in 2021, then jumped by 183.57% to $15795.0 in 2022, then sank by 69.47% to $4822.0 in 2023, then slumped by 43.59% to $2720.0 in 2024.
• The last three Cost of Revenue figures came in at $2720.0 (Q4 2024), $4822.0 (Q4 2023), and $12747.0 (Q2 2023), per Business Quant data.